UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury

Neurorehabilitation and neural repair, 2018-06, Vol.32 (6-7), p.578-589

2018

Volltextzugriff (PDF)

Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects

Science (American Association for the Advancement of Science), 2009-07, Vol.325 (5939), p.490-493

2009

Volltextzugriff (PDF)

Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety

Drug metabolism and disposition, 2009-04, Vol.37 (4), p.827-833

2009

Volltextzugriff (PDF)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Blood, 2023-03, Vol.141 (9), p.971-983

2023

Volltextzugriff (PDF)

Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti‐C5 monoclonal antibody tesidolumab

American journal of transplantation, 2020-09, Vol.20 (9), p.2581-2588

2020

Volltextzugriff (PDF)

CYP3A but not P‐gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta‐specific phosphoinositide‐3 kinase inhibitor leniolisib

Biopharmaceutics & drug disposition, 2018-09, Vol.39 (8), p.394-402

2018

Volltextzugriff (PDF)

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

British journal of pharmacology, 2015-03, Vol.172 (5), p.1292-1304

2015

Volltextzugriff (PDF)

Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship

Epilepsia (Copenhagen), 2015-06, Vol.56 (6), p.924-932

2015

Volltextzugriff (PDF)

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

Blood, 2018-11, Vol.132 (Supplement 1), p.3706-3706

2018

Volltextzugriff (PDF)

Chronopharmacology of intravenous and oral modified release verapamil

British journal of clinical pharmacology, 1999-04, Vol.47 (4), p.413-419

1999

Volltextzugriff (PDF)

Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study

Progress in brain research, 2021, Vol.260, p.423-440

2021

Volltextzugriff (PDF)

RESULTS FROM A FIRST-IN-HUMAN STUDY WITH THE BACE INHIBITOR CNP520

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P200-P200

2016

Volltextzugriff (PDF)

O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_4), p.P200-P200

2016

Volltextzugriff (PDF)

AQW051, a novel, potent and selective [alpha]7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

British journal of pharmacology, 2015-03, Vol.172 (5), p.1292

2015

Volltextzugriff (PDF)

AQW 051, a novel, potent and selective α 7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

British journal of pharmacology, 2015-03, Vol.172 (5), p.1292-1304

2015

Volltextzugriff (PDF)

Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study

Psychopharmacologia, 2007-07, Vol.192 (4), p.479-487

2007

Volltextzugriff (PDF)

Analysis of fibrin formation and proteolysis during intravenous administration of ancrod

Blood, 2000-10, Vol.96 (8), p.2793-2802

2000

Volltextzugriff (PDF)

Analysis of fibrin formation and proteolysis during intravenous administration of ancrod

Blood, 2000-10, Vol.96 (8), p.2793-2802

2000

Volltextzugriff (PDF)

Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity

Annals of the New York Academy of Sciences, 2001-01, Vol.936 (1), p.210-214

2001

Volltextzugriff (PDF)

Plasminogen Activation Without Changes in tPA and PAI-1 in Response to Subcutaneous Administration of Ancrod

Thrombosis research, 2001-12, Vol.104 (6), p.433-438

2001

Volltextzugriff (PDF)

Fibrin Formation and Proteolysis during Ancrod Treatment

Annals of the New York Academy of Sciences, 2001-06, Vol.936 (1), p.210-214

2001

Volltextzugriff (PDF)

Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism

Circulation (New York, N.Y.), 2014-01, Vol.129 (4), p.479-486

2014

Volltextzugriff (PDF)

Deutsch als Zweitsprache und inklusive Bildung

2023

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(81)

Publikationsform

Sprache

Deutsch
(48)
Englisch
(37)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Humans
(18)
Life Sciences & Biomedicine
(16)
Male
(13)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Adult
(9)
Female
(9)
Middle Aged
(8)
Cardiovascular System & Cardiology
(5)
Pharmacology. Drug Treatments
(5)
Adolescent
(4)
Aged
(4)
Dose-Response Relationship, Drug
(4)
Double-Blind Method
(4)
Fibrinolytic Agents - Administration & Dosage
(4)
Hematology
(4)
Neurosciences & Neurology
(4)
Pharmacology
(4)
Pharmacology & Pharmacy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury

Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects

Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti‐C5 monoclonal antibody tesidolumab

Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021

CYP3A but not P‐gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta‐specific phosphoinositide‐3 kinase inhibitor leniolisib

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

Chronopharmacology of intravenous and oral modified release verapamil

Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study

RESULTS FROM A FIRST-IN-HUMAN STUDY WITH THE BACE INHIBITOR CNP520

O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520

AQW051, a novel, potent and selective [alpha]7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

AQW 051, a novel, potent and selective α 7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study

Analysis of fibrin formation and proteolysis during intravenous administration of ancrod

Analysis of fibrin formation and proteolysis during intravenous administration of ancrod

Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity

Plasminogen Activation Without Changes in tPA and PAI-1 in Response to Subcutaneous Administration of Ancrod

Fibrin Formation and Proteolysis during Ancrod Treatment

Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism

Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism

Deutsch als Zweitsprache und inklusive Bildung

Suchergebnisse filtern